Effectiveness of early Anakinra on cardiac function in children with multisystem inflammatory syndrome of COVID-19: a systematic review.
Muhammed ShabilMahalaqua Nazli KhatibGodfrey T BandaQuazi Syed ZahiruddinSuhas BallalPooja BansalManish SrivastavaIsha AroraM Ravi KumarAashna SinhaKumud PantJumana M Al-JishiHawra AlbayatMona A Al FaresMohammed GaroutHayam A AlrasheedMaha F Al-SubaieAli A RabaanPublished in: BMC infectious diseases (2024)
Early Anakinra administration shows potential for improving cardiac function and reducing inflammation in children with MIS-C, particularly those with severe manifestations. However, the existing evidence is limited by the observational nature of most studies and lacks randomized controlled trials (RCTs). Further high-quality RCTs are necessary to conclusively determine Anakinra's effectiveness and optimize its use in MIS-C management for better long-term cardiac outcomes and standardized treatment protocols.